Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam and Isis Pen Alliance for RNAi Therapeutics

NEW YORK, March 12 (GenomeWeb News) - Isis Pharmaceuticals and Alnylam Pharmaceuticals will jointly develop and commercialize RNAi therapeutics, Isis said yesterday.


Under the agreement, Alnylam gains exclusive access to more than 150 of Isis' US patents for use in modifying double-stranded oligonucleotides. Alnylam's access also includes the "Crooke" patents, which cover fundamental mechanisms for Rnase-dependent antisense activity and chemically modified oligonucleotides. In addition, Isis will make a $10 million equity investment in Alnylam and give the company access to its manufacturing facilities and expertise for developing RNAi therapeutics. Moreover, Isis will pay Alnylam milestone fees and royalties on any RNAi-based drugs resulting from Alnylam's technologies.


In return, Cambridge, Mass.-based Alnylam will pay Isis a $5 million technology access fee, contribute to partnering fees, and make downstream milestone and royalty payments.


The companies will also share proceeds from licenses Alnylam grants under a previously announced program that include sublicenses to Isis' patents. Isis, based in Carlsbad, Calif., will retain certain rights to a number of targets for double-stranded RNAi drugs.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.